TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair

Core Insights - TELA Bio, Inc. has launched OviTex Inguinal Reinforced Tissue Matrix in Europe, specifically designed for laparoscopic and robotic-assisted inguinal hernia repair [1][6] - The product follows a successful U.S. launch in 2024, achieving over $1 million in sales in its first year [2] - OviTex Inguinal offers two configurations in Europe, enhancing compatibility with laparoscopic and robotic procedures [3] Product Details - OviTex Inguinal is part of the OviTex portfolio, utilizing layers of ovine rumen interwoven with polymer for added strength while minimizing permanent polymer footprint [4] - The product has over 8 years of clinical experience with more than 69,000 implantations and over 40 published works demonstrating its clinical efficacy [4] - A study showed a low 1.2% recurrence rate in patients undergoing robotic inguinal hernia repair using the ReBAR technique, with an average follow-up of 1.5 years [5] Market Opportunity - The expansion of robotic-assisted procedures in Europe presents significant opportunities for naturally derived devices like OviTex Inguinal [6] - The product aligns with the European market's emphasis on shared decision-making between surgeons and patients, making it a compelling option for clinical performance and patient expectations [6] Company Overview - TELA Bio, Inc. focuses on innovative technologies that optimize clinical outcomes by preserving and restoring the patient's anatomy [8] - The company aims to provide advanced, economically effective soft-tissue reconstruction solutions while minimizing long-term exposure to synthetic materials [8] Indications for Use - OviTex Reinforced Tissue Matrix is intended for surgical mesh applications to reinforce and repair soft tissue weaknesses, including inguinal hernias [9]